Domestic pharmaceutical company China Resources Sanjiu reported solid gains during the 14th Five-Year Plan period (2021–25), driven by innovation, green development, and global vision.

The Shenzhen, Guangdong province-based company achieved steady growth in scale and profitability, with a compound annual growth rate of about 23.6 percent in revenue and 24.5 percent in total profit over the past three years, according to the company.

At the same time, CR Sanjiu continued to deliver robust returns to its shareholders. Since its listing, the firm has raised 1.67 billion yuan ($234.1 million) through stock issuance while distributing around 9.32 billion yuan in dividends — more than five times its actual fundraising.

Innovation has played a central role in its growth trajectory. The company's research and development investment rose from 581 million yuan in 2020 to 953 million yuan in 2024, marking a 64 percent increase. As of the first half of 2025, it had 205 research projects underway, covering key therapeutic areas such as cardiovascular and metabolic diseases, oncology, respiratory illnesses, neurology and psychiatry, gastroenterology, and dermatology, the company said.

In advancing sustainability goals, it has also embedded the dual carbon goals into its business operations. In 2025, its MSCI ESG rating was raised by two notches to A, underscored by strengthened green transition and sustainability capabilities.

As a major player in strengthening the traditional Chinese medicine sector, the company has actively pursued strategic acquisitions. In January 2023, it acquired a 28 percent stake in Kunming, Yunnan province-based KPC Pharmaceuticals, completing the first A-share acquisition of its kind to qualify as a major asset restructuring.

In March 2025, it followed with another landmark deal, acquiring a 28 percent stake in Tianjin-based Tasly, marking the second such transaction during the 14th Five-Year Plan. 

The three enterprises now form a complementary structure to build differentiated competitiveness through deepened collaboration. CR Sanjiu positions itself with consumer healthcare at the core to become an industry leader, while Tasly focuses on prescription drugs, and KPC Pharmaceuticals leverages its flagship TCM products to target the silver economy.

Looking ahead, as the company prepares to conclude the 14th Five-Year Plan and map out the 15th, CR Sanjiu said it will continue to shoulder its responsibility as a centrally administered State-owned enterprise, sharpen its core business focus, and accelerate innovation-driven transformation. By doing so, the drugmaker aims to offer "Chinese wisdom" and "Chinese solutions" for human well-being, it said.

lijiaying@chinadaily.com.cn

Editor's note: The China Association for Public Companies, together with China Daily and other media outlets, has launched the initiative Listed Companies in Action: My Five Years in the 14th Five-Year Plan (2021-25), highlighting the achievements of Chinese listed companies in advancing high-quality development.

Heng Lin Home Furnishings Co Ltd, a furniture and home furnishings manufacturer based in Anji, Zhejiang province, boosted research and development investment and innovation capacity during the 14th Five-Year Plan period (2021-25).

In 2024, the company's R&D spending climbed to 226 million yuan ($31.65 million), the highest since it went public on the Shanghai Stock Exchange in 2017. By the end of the year, it held 1,630 valid patents, including 142 invention patents.

Revenue surpassed 10 billion yuan for the first time in 2024, reaching 11.03 billion yuan — a 34.6 percent increase from a year earlier, according to its earnings report.

To navigate a complex global trade environment, Heng Lin has expanded its international footprint by establishing production bases in Vietnam and Switzerland, aiming to mitigate risks and improve operational efficiency. By the end of 2024, overseas assets totaled 5.77 billion yuan, accounting for 53.18 percent of its total assets.

The company has also built a global supply chain network, including 11 warehousing and logistics centers worldwide. Its overseas warehouses span 4 million square meters, enabling delivery within one to three days across the United States and strengthening competitiveness in cross-border e-commerce and bulk sales.

Heng Lin maintains long-term partnerships with leading global retailers such as Ikea, Nitori, Home Depot and Amazon. Its products are sold in more than 80 countries and regions.